Tetra Bio-Pharma

85 articles with Tetra Bio-Pharma

• 

  BioSpace Global Roundup: Companies Slash Prices to Meet China's Health Coverage

  12/31/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada

  12/30/2020

  The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of the year

• Tetra Bio-Pharma Confirms it is on Track to Receive Government Funding

  12/21/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, announced that it expects government funding to help accelerate its sepsis and acute respiratory distress syndrome drug development.

• Tetra Bio-Pharma Hits Another Milestone Before Year End

  12/16/2020

  Tetra will accelerate its Inhaled synthetic THC drug approvals under a 505(b)(2) marketing application pathway FDA confirms clinical development program to support marketing application of Tetras inhaled innovative THC drug

• Tetra Bio-Pharma Provides Update on Market Potential for QIXLEEF(TM)

  12/7/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, provided an update on the potential US market for QIXLEEF™, a botanical cannabinoid-derived medicine that meets USA cGMP regulatory requirements.

• Tetra Bio-Pharma Completes Major Milestone for COVID-19 Therapeutic

  12/2/2020

  Tetra Bio-Pharma Inc. ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announced it has completed Investigational New Drug (IND) -enabling toxicology, clearing the way for human clinical trials for its novel drug candidate ARDS-003.

• Tetra Bio-Pharma Provides Update on Recent Milestones

  11/16/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, provided an update on its ARDS-003, CAUMZ™, PPP-003 and QIXLEEF™ programs.

• Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003

  11/4/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on the potential market of its new drug, ARDS-003

• Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.

  10/28/2020

  Tetra Bio-Pharma Inc. today announces that it has completed the divestiture of Lumiera Health Innovation Inc. ("Lumiera"), its subsidiary, to Mondias Natural Products Inc. (TSXV: NHP) ("Mondias ") as previously announced.

• Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

  10/22/2020

  Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration

• Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx

  10/21/2020

  Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug

• IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol

  10/21/2020

  IntelGenx Corp. announced that it has entered into an amended and restated license agreement granting Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, additional exclusive worldwide rights, including the right to manufacture, IntelGenx’s Adversa® mucoadhesive delivery technology.

• Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury

  10/20/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, announced the results of an experimental study of its ARDS-003 investigational new drug in a model of lung injury.

• Tetra Bio-Pharma Adds Two Board Members and Appoints New COO

  9/17/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Ms. Dale Weil and Dr. Brent Norton have been appointed to the Company's Board of Directors and Dr. Graham Wood, Ph.D. has been appointed as Chief Operating Officer.

• Tetra Bio-Pharma Appoints Chief Financial Officer

  9/11/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Jean-Francois Boily, CPA, CA, as Chief Financial Officer and member of the Company's executive team.

• Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy

  9/4/2020

  Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis space

• Tetra Bio-Pharma Announces Data on its CBD Metabolite Study in Humans

  8/27/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has mapped out CBD metabolites in humans who were administered QIXLEEF™ by vaporization.

• Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003

  8/18/2020

  Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product

• Tetra Bio-Pharma Inc. Virtually Opens The Market

  8/7/2020

  Dr. Guy Chamberland , CEO and Chief Regulatory Officer, Tetra Bio-Pharma Inc. (TSX: TBP), joined his team and Sophie Van Houtte , Head of Company Services, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market. Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid

• CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities

  8/6/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to accelerate its European activities.